Usage Examples
- The dose escalation is a change in protocol, so it goes to FDA as a protocol amendment before any site implements it.
- We added two sites this month, so the new investigators go in as a protocol amendment within 30 days.
- The IRB cleared the amendment Friday, but we cannot implement until the submission is in FDA's hands.
What is Protocol Amendment?
A protocol amendment is the IND submission that adds a new clinical protocol, changes an existing protocol, or adds an investigator; protocol changes must be submitted to FDA and approved by the IRB before implementation.
Protocol amendments exist because an IND is a live application, not a filing event. FDA's review of an investigational drug rests on the protocols sitting in the application, so 21 CFR 312.30 obliges a sponsor to amend the IND as needed to ensure the clinical investigations are conducted according to the protocols it contains. Without that standing duty, the file on record and the trial actually running silently diverge.
Protocol amendments cover three triggers under 21 CFR 312.30: a new protocol for a study not covered by an existing one, a change to a protocol already in the IND, and the addition of a new investigator. Not every protocol change qualifies. In Phase 1 the trigger is a change affecting subject safety; in Phases 2 and 3 it is a change significantly affecting safety of subjects, the scope of the investigation, or the scientific quality of the study.
Protocol amendments are gated on two independent conditions in practice. A change may be implemented once the sponsor has submitted it to FDA for review and the IRB has approved it, in either order for a new protocol. FDA issues no affirmative approval of the amendment, but the submission must precede implementation. The single exception is a change addressing an apparent immediate hazard to subjects.
Not to be confused with
- New protocol vs. change in protocol
- both are protocol amendments under 21 CFR 312.30, but a new protocol covers a study the IND does not yet describe, while a change in protocol modifies one already in the application. The new protocol has no prior version to version-control; the change does.
- New investigator amendment
- adding an investigator is a protocol amendment reported to FDA within 30 days of the investigator being added, so it is the one category filed after the fact. Every other protocol amendment must be submitted before implementation.
- Immediate-hazard change
- a change to eliminate an apparent immediate hazard to subjects may be implemented immediately. That removes the waiting period, not the amendment; the sponsor still submits and the IRB is still notified.
- Protocol deviation
- a deviation is a departure from the protocol as written and leaves the approved document unchanged. A protocol amendment changes the document itself, which is why a pattern of repeated deviations is usually evidence that an amendment was needed and never filed.
Under an IND, protocol amendment duties fall on the sponsor and the investigator at the same time.
What you must do
- 1Submit a new protocol to FDA and obtain IRB approval before the study begins; the two conditions may be satisfied in either order21 CFR 312.30(a)
- 2Submit a protocol change to FDA and obtain IRB approval before implementing it, where the change affects subject safety in Phase 1 or significantly affects safety of subjects, the scope of the investigation, or the scientific quality of the study in Phase 2 or 321 CFR 312.30(b)
- 3Notify FDA of a new investigator within 30 days of the investigator being added21 CFR 312.30(c)
- 4File the protocol amendment before implementation, not after; timing is the obligation, not merely content21 CFR 312.30(e)
- 5As investigator, make no change in the research without IRB approval except where necessary to eliminate apparent immediate hazards, and promptly report all changes in research activity to the IRB21 CFR 312.66
Common mistakes
Implementing on IRB approval alone
sites treat the IRB letter as the green light and start screening under the new criteria. 21 CFR 312.30(b) requires both IRB approval and submission of the change to FDA, and 312.30(e) requires the submission before implementation. Subjects enrolled in the gap were enrolled under a protocol FDA had not received.
Stretching the immediate-hazard exception
the exception in 21 CFR 312.30(b) and 312.66 is narrow: a change necessary to eliminate an apparent immediate hazard to subjects. Using it for enrollment pressure, a competitive timeline, or a supply problem converts an approved shortcut into an unapproved protocol change with no defensible rationale in the trial master file.
Letting the 30-day investigator clock run past the site activation
21 CFR 312.30(c) puts its own deadline on adding an investigator, independent of any other amendment in flight. Teams batch site additions with the next substantive amendment and miss the window, producing a documented gap between when a site started work and when FDA was told it existed.
When This Matters
- The dose escalation is a change in protocol, so it goes to FDA as a protocol amendment before any site implements it.
- We added two sites this month, so the new investigators go in as a protocol amendment within 30 days.
- The IRB cleared the amendment Friday, but we cannot implement until the submission is in FDA's hands.
Frequently Asked Questions
No. Under 21 CFR 312.30(b), a Phase 1 change requires an amendment only if it affects subject safety, and a Phase 2 or 3 change only if it significantly affects safety of subjects, the scope of the investigation, or the scientific quality of the study.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
